Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Futuximab/modotuximab - Symphogen

Next Previous
Drug Profile

Futuximab/modotuximab - Symphogen

Alternative Names: 992-and-1024; 992/1024; DS 992/DS 1024; DS-1024/DS-992; Modotuximab/futuximab; S-95026; Sym-004

Latest Information Update: 21 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Symphogen
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II Glioma
  • No development reported Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer

Most Recent Events

  • 28 Jun 2023 Adverse events data from a phase III COLSTAR trial in Colorectal cancer presented at the 25th World Congress on Gastrointestinal Cancer (WCGC-2023)
  • 05 Jul 2022 Phase-III clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Japan, Poland, Hungary, Belgium (IV) (NCT05223673) (EudraCT2021-003151-41)
  • 11 Jan 2022 Phase-III clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Finland (IV) (EudraCT2021-003151-41)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top